HLA DQA1*05 typing (immunogenicity)

Test covered by the reimbursement:

YES

Gender:

Woman/Man

Material:

Peripheral blood, Buccal swab …

Turnover time:

3 weeks

STATIM:

1 week

Material:

Peripheral blood | 1x 3 ml of whole blood in K3 EDTA tube

Storage after examination: week after the report is issued 2 – 8°C

Buccal swab | 2x swab stick for buccal swab collection

Storage after examination: week after the report is issued 2 – 8°C

Isolated DNA from blood | 10–100 ng/μL of isolated DNA from blood in a PCR tube of at least 15 μL.

Storage after examination: stored in a DNA archive without restriction 15°C

Quick test description:

Detection of the presence of HLA DQA1*05*01 and HLA DQA1*05*05 alleles by real-time PCR.

Test details:

The presence of two high-risk alleles is demonstrated – HLA-DQA1*05:01 allele that have been shown to be present in patients with Crohn’s disease treated with anti-TNF drugs, which, according to association studies, is significantly related to immunogenicity (rate of antibody formation) against infliximab, and the HLA-DQA1*05:05 allele which, according to association studies, is significantly associated with immunogenicity against adalimumab in these patients. Antibodies may lead to the ineffectiveness of biological therapy and may be a source of early and delayed hypersensitivity reactions to the biological drug. The test is performed using real-time PCR, which is based on the determination of HLA DQA1*05*01 and HLA DQA1*05*05 alleles by diagnostic kit.

back to list